BofA analyst Geoff Meacham raised the firm’s price target on Vertex Pharmaceuticals to $400 from $350 and keeps a Buy rating on the shares. The firm has “above consensus” top and bottom-line forecasts for Vertex in Q2 as it continues to expect outperformance on the CF franchise, the analyst tells investors in an an earnings preview for the U.S. Biopharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VRTX:
- Vertex Pharmaceuticals granted approval for label extension of Orkambi
- Vertex Pharmaceuticals price target raised to $340 from $305 at Morgan Stanley
- Sigilon Therapeutics downgraded to Neutral from Buy at BTIG
- Vertex Pharmaceuticals price target raised to $360 from $350 at TD Cowen
- Vertex Pharmaceuticals’ VX-880 showed treatment benefit, says BMO Capital